Androgen deprivation therapy (ADT) is the cornerstone of treatment for hormone-sensitive advanced prostate cancer, which is usually achieved with the use of gonadotrophic-releasing hormone (GnRH) analogs [1,2]. This evidence concerns the gene GNRH1 and prostate carcinoma.